141 related articles for article (PubMed ID: 38630023)
1. Coaxial dual-path electrochemical biosensing and logic strategy-based detection of lung cancer-derived exosomal PD-L1.
Liu J; Liu Z; Zhao C; Jiao Y; Li B; Shi J; Chen Z; Zhang Z
Nanoscale; 2024 May; 16(18):8950-8959. PubMed ID: 38630023
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe.
Qin X; Xiang Y; Li N; Wei B; Chen Y; Fang D; Fang M; Li Q; Liu J; Tang Y; Li X; Yang F
Biosens Bioelectron; 2022 Nov; 216():114636. PubMed ID: 35986985
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
[TBL] [Abstract][Full Text] [Related]
4. Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis.
Liu C; Zeng X; An Z; Yang Y; Eisenbaum M; Gu X; Jornet JM; Dy GK; Reid ME; Gan Q; Wu Y
ACS Sens; 2018 Aug; 3(8):1471-1479. PubMed ID: 30019892
[TBL] [Abstract][Full Text] [Related]
5. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
6. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
7. Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.
Zhu L; Xu Y; Kang S; Lin B; Zhang C; You Z; Lin H; Yang C; Song Y
Small Methods; 2022 Sep; 6(9):e2200549. PubMed ID: 35810463
[TBL] [Abstract][Full Text] [Related]
8. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract][Full Text] [Related]
9. Multivalence-Actuated DNA Nanomachines Enable Bicolor Exosomal Phenotyping and PD-L1-Guided Therapy Monitoring.
Jin D; Peng XX; Qin Y; Wu P; Lu H; Wang L; Huang J; Li Y; Zhang Y; Zhang GJ; Yang F
Anal Chem; 2020 Jul; 92(14):9877-9886. PubMed ID: 32551501
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract][Full Text] [Related]
11. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
[TBL] [Abstract][Full Text] [Related]
12. ExoPD-L1: an assistant for tumor progression and potential diagnostic marker.
Hu R; Jahan MS; Tang L
Front Oncol; 2023; 13():1194180. PubMed ID: 37736550
[TBL] [Abstract][Full Text] [Related]
13. Microporous PdCuB nanotag-based electrochemical aptasensor with Au@CuCl
Chang L; Wu H; Chen R; Sun X; Yang Y; Huang C; Ding S; Liu C; Cheng W
J Nanobiotechnology; 2023 Mar; 21(1):86. PubMed ID: 36906540
[TBL] [Abstract][Full Text] [Related]
14. Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-Specific Glycosylation.
Zhu L; Xu Y; Wei X; Lin H; Huang M; Lin B; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Aug; 60(33):18111-18115. PubMed ID: 34043264
[TBL] [Abstract][Full Text] [Related]
15. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
16. Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR.
Lin B; Tian T; Lu Y; Liu D; Huang M; Zhu L; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Mar; 60(14):7582-7586. PubMed ID: 33382182
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare.
Zouein J; Kesrouani C; Kourie HR
Immunotherapy; 2021 Aug; 13(12):1053-1065. PubMed ID: 34190579
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 exosomes electrochemical sensor based on coordination of AgNCs and Zr
Hu J; Mao Z; Lu Y; Chen Q; Xia J; Deng H; Chen H
Biosens Bioelectron; 2023 Sep; 235():115379. PubMed ID: 37207581
[TBL] [Abstract][Full Text] [Related]
19. Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode.
Niedziałkowski P; Bojko M; Ryl J; Wcisło A; Spodzieja M; Magiera-Mularz K; Guzik K; Dubin G; Holak TA; Ossowski T; Rodziewicz-Motowidło S
Bioelectrochemistry; 2021 Jun; 139():107742. PubMed ID: 33517203
[TBL] [Abstract][Full Text] [Related]
20. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
